Bristol-Myers Squibb (NYSE:BMY) generates its revenues from its Oncology, Cardiovascular, Immunology, Virology, along with its Mature Drugs & Other segment. The segment revenues have grown from $1.9 billion in 2015 to $4.9 billion in 2017, led by its blockbuster drug Eliquis. We forecast the segment revenues to grow in mid-20 percents in 2018 and in low-mid single digits in the later years. However, Orencia’s patent exclusivity in the U.S. expires in 2019, while the EU patent exclusivity ended in 2017. Most of the drugs in this segment have lost patent exclusivity, and face biosimilar competition.

Source: Forbes September 10, 2018 18:11 UTC